Bone Marrow Biopsy Device to Bolster Bone Cancer Treatment in India

A newly patented biopsy device is expected to boost the Indian bone cancer treatment landscape, helping to determine treatment options for the deadly disease, according to GlobalData.

Bone marrow cancer is one of the most prevalent forms of the disease in India, affecting a significant portion of the population. Treatment options—typically decided by a bone marrow biopsy—could include chemotherapy, radiation therapy, and a bone marrow transplant. 
 
Doctors and faculty members from the Gujrat Cancer Research Institute (GCRI) and the Institute of Infrastructure Technology Research and Management (IITRAM) have recently partnered to design a bone marrow biopsy device that provides clinicians with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone, which simplifies the tissue extraction process. 
 
GlobalData’s research reveals that India’s biopsy needle devices, which account for close to 12% of the Asia-Pacific (APAC) market in 2023, is expected to grow nearly 3% annually through 2030. 
 
“Nerve and blood vessel damage, bone fracture, uncontrolled bleeding from the site of incision, and high chances of infection are some of the risks associated with the conventional needle bone biopsies,” GlobalData Medical Devices Ayshi Ganguly said. “Some other consequences include fluid retention at the biopsy site and even over and under-extraction of tissue for examination. This newly patented device is expected to mitigate these risks associated with needle biopsies and reduce accidental damage to tissues and bones.” 
 
The device has also been granted an Indian patent. Doctors can now limit the risk associated with manual or electric needles using a force-balancing mechanism that mitigates the forceful thrusting of needles into bones, ensuring the safe extraction of the optimal amount of tissue for diagnosis. This device is also aided with additional depth sensors and pressure control technology to increase accuracy and efficiency.
 
“The introduction of a new bone marrow biopsy device is expected to yield positive implications for medical diagnosis in India. In addition, the FDA and CE regulatory approvals in the future will help market this device across geographies. The device has the potential to disrupt the Indian bone marrow biopsy market as it scores over conventional biopsy needles and will eventually boost the bone cancer diagnosis ecosystem in India,” Ganguly stated.